← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Astrotech revenue fell 41.2% to $1.0M, losses widened, FCF fell to -$13.8M, and accounting screens were severe.
The read at a glance✓ Audited against SEC data
- Business mix — Mass spectrometry detection productsNote
- Revenue — Revenue fell 41.2%Watch
- Losses — Net loss widened to $13.9MWatch
- Cash — FCF was -$13.8MWatch
- Balance sheet — Equity fell 36.5%Watch
- Insiders — 0 buys / 1 sellWatch
- Accounting — Altman-Z distress; Beneish flag; EQ distressWatch
Business
Astrotech is commercializing mass spectrometry and gas chromatography technology through detection products and related subsidiaries.
Where the revenue comes from
Fiscal 2025, as ASTROTECH Corp reports it. History and quarterly detail are in the app.
- Product$804K
- Service$130K
- Grant$115K
Leadership changes
From ASTROTECH Corp's own filings, the day they're filed.
- Scott Bartley · Chief Financial Officer · appointmenteff. 2025-10-27
- Jennifer Canas · Chief Financial Officer · departureeff. 2025-10-17
- Nihanth Badugu · Chief Operating Officer · appointmenteff. 2025-08-13
Latest filings
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ASTROTECH Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.